Trial Profile
An Open Label, Randomised, Phase II Study to Investigate the Efficacy and Safety of ALECSAT Treatment as an add-on Therapy to Radiotherapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Cancer vaccine-ALECSAT (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms ALECSAT
- Sponsors CytoVac
- 18 Aug 2022 Status changed from completed to discontinued.
- 28 Apr 2020 Status changed from active, no longer recruiting to completed.
- 25 Feb 2019 Planned number of patients changed from 87 to 62.